Niagen Bioscience Posts 16% Q4 Growth and Secures Patent for Injectable NR
Niagen Bioscience delivered 16% year-on-year Q4 2025 revenue growth to $33.8 million and 30% full-year net revenue growth to $129.4 million, ending with $64.8 million cash and no debt. The company secured a patent for intravenous and injectable NR formulations but lowered 2026 revenue guidance to 10–15%.
1. Q4 2025 Financial Performance
Niagen Bioscience achieved 16% year-over-year Q4 revenue growth to $33.8 million and 30% net revenue growth to $129.4 million for the full year, while general and administrative expenses rose by $8.7 million driven by higher employee costs and stock-based compensation.
2. Strong Balance Sheet and Patent Milestone
The company closed 2025 with $64.8 million in cash, zero debt and secured a patent covering NR and derivatives in intravenous and injectable formulations, positioning it to expand product offerings.
3. Clinical Pipeline and Competitive Challenges
Niagen has published 29 NAD studies including eight clinical trials, but its No Park Parkinson’s study missed the primary endpoint and faces heightened competition and FDA reversal on NMN supplement status, triggering industry litigation.
4. Conserved 2026 Guidance and Product Strategy
Management set 2026 revenue growth guidance at 10–15%, citing a conservative approach, and outlined plans for an initial injectable SKU targeting biohackers with a lower-priced self-injection syringe ahead of a simplified pen format.